Peter Mark Roget: physician, scientist, systematist; his thesaurus and his impact on 19th-century neuroscience.

Prog Brain Res

Department of Neurobiology, The David Geffen School of Medicine, University of California, Los Angeles, CA, USA. Electronic address:

Published: June 2014

Peter Mark Roget (1779-1869) is best known for his Thesaurus, a project completed late in his long life. He trained as a physician, practiced medicine, and was interested in many branches of science. Much of his life was dedicated to the systematization of knowledge and identifying relationships. Although not an experimentalist in the modern sense of the word, he contributed to "neuroscience" in journal and encyclopaedia articles, as well as in books and lectures. He wrote extensively on comparative physiology, sensory systems, phrenology, optics, and various disorders affecting the nervous system. He viewed his two-volume Bridgewater Treatise of 1834 as his most significant achievement, turning to physiology and comparative anatomy to argue that God's existence can be seen in how living forms and their components are designed. Roget was active in many scholarly organizations, most notably the Royal Society of London, where he served for more than two decades as its secretary before "retiring" to pursue his Thesaurus.

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-444-63273-9.00010-1DOI Listing

Publication Analysis

Top Keywords

peter mark
8
mark roget
8
roget physician
4
physician scientist
4
scientist systematist
4
systematist thesaurus
4
thesaurus impact
4
impact 19th-century
4
19th-century neuroscience
4
neuroscience peter
4

Similar Publications

High-fat diet (HFD)-induced obesity represents a significant challenge to male reproductive health, affecting approximately 13% of the global adult population. This comprehensive review synthesizes current evidence regarding mulberry ( L.) fruit extract's therapeutic potential for HFD-induced male reproductive dysfunction.

View Article and Find Full Text PDF

Clinical Outcomes in Patients Undergoing Sequential Intragastric Balloon (IGB) Treatment for Super Obesity: A Single Centre Retrospective Analysis.

J Metab Bariatr Surg

December 2024

Department of General Surgery, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, Yorkshire, United Kingdom.

Purpose: We aimed to assess outcomes in patients undergoing sequential intragastric balloon (IGB) treatment for obesity.

Materials And Methods: Consecutive patients who underwent treatment between May 2014 and February 2023 were identified. We recorded outcomes including: weight at 3-monthly intervals, progression to definitive bariatric procedure and morbidity.

View Article and Find Full Text PDF
Article Synopsis
  • Older adults (65+) represent a significant portion of emergency laparotomy cases in the UK, yet there's limited data on patients who require surgery but do not undergo it, referred to as NoLap patients.
  • A study across 64 surgical centers tracked 750 NoLap patients over a 90-day period and found that 60% were female with a median age of 83, most suffering from frailty and severe comorbidities, leading to a high 90-day mortality rate of 79%.
  • The findings highlight the complex medical challenges faced by NoLap patients, with a small percentage surviving long-term but requiring increased care, emphasizing the need for further research on the decision-making process surrounding surgery in this high-risk group.
View Article and Find Full Text PDF

Introduction: Early-stage lung cancer diagnosis through detection of nodules on computed tomography (CT) remains integral to patient survivorship, promoting national screening programmes and diagnostic tools using artificial intelligence (AI) convolutional neural networks (CNN); the software of AI-Rad Companion™ (AIRC), capable of self-optimising feature recognition. This study aims to demonstrate the practical value of AI-based lung nodule detection in a clinical setting; a limited body of research.

Methods: One hundred and eighty-three non-contrast CT chest studies from a single centre were assessed for AIRC software analysis.

View Article and Find Full Text PDF
Article Synopsis
  • Dysferlinopathies are a type of muscular dystrophy caused by mutations that lead to a deficiency of the protein dysferlin, resulting in muscle wasting and inflammation, with no available treatments.
  • Glucocorticoids, commonly used for reducing inflammation in muscular dystrophies, have been found to worsen conditions in dysferlinopathy patients by accelerating muscle strength loss.
  • Research on mice with dysferlin deficiency revealed that glucocorticoid treatment exacerbates muscle damage and alters gene expression related to inflammation and metabolism, indicating the need for alternative therapeutic strategies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!